2021-02315. Importer of Controlled Substances Application: Mylan Pharmaceuticals Inc.  

  • Start Preamble

    AGENCY:

    Drug Enforcement Administration, Justice.

    ACTION:

    Notice of application.

    SUMMARY:

    Mylan Pharmaceuticals Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

    DATES:

    Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 8, 2021. Such persons may also file a written request for a hearing on the application on or before March 8, 2021.

    ADDRESSES:

    Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In accordance with 21 CFR 1301.34(a), this is notice that on December 18, 2020, Mylan Pharmaceuticals Inc., 2898 Manufacturers Road, Greensboro, North Carolina 27406-4600, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

    Controlled substanceDrug codeSchedule
    Remifentanil9739II

    The company plans to import the above-controlled substance as the Federal Drug Administration-approved drug product in finished dosage form for commercial distribution to its customers. Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2).

    Start Signature

    William T. McDermott,

    Assistant Administrator.

    End Signature End Supplemental Information

    [FR Doc. 2021-02315 Filed 2-3-21; 8:45 am]

    BILLING CODE P

Document Information

Published:
02/04/2021
Department:
Drug Enforcement Administration
Entry Type:
Notice
Action:
Notice of application.
Document Number:
2021-02315
Dates:
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 8, 2021. Such persons may also file a written request for a hearing on the application on or before March 8, 2021.
Pages:
8220-8220 (1 pages)
Docket Numbers:
Docket No. DEA-773
PDF File:
2021-02315.pdf